ERBB2 and cholangiocarcinoma: ERBB2 mutations are a frequent event in solid tumors, and the combination of trastuzumab and lapatinib has shown promising antitumoral effects in four different ERBB2-positive tumor entities as adenosarcoma, endometrial cancer, cholangiocarcinoma, and colorectal cancer (13).